« Back to Record
Citation APA

Cooper, D., Heera, J., Goodrich, J., Tawadrous, M., Saag, M., Dejesus, E., Clumeck, N., Walmsley, S., Ting, N., Coakley, E., Reeves, J., Reyes-Teran, G., Westby, M., Van Der Ryst, E., Lve, P., Mohapi, L., Mingrone, H., Horban, A., Hackman, F., Sullivan, J., & Mayer, H. (2010). Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. The Journal of infectious diseases, 201(6), 803-813. doi:10.1086/650697


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/84274

Cooper, D., Heera, J., Goodrich, J., Tawadrous, M., Saag, M., Dejesus, E., Clumeck, N., Walmsley, S., Ting, N., Coakley, E., Reeves, J., Reyes-Teran, G., Westby, M., Van Der Ryst, E., Lve, P., Mohapi, L., Mingrone, H., Horban, A., Hackman, F., Sullivan, J., & Mayer, H. (2010). Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. The Journal of infectious diseases, 201(6), 803-813. doi:10.1086/650697